UBS Maintains a 'Sell' on athenahealth (ATHN); Raising Numbers on Suspected Conservatism

February 16, 2012 1:51 PM EST
Get Alerts ATHN Hot Sheet
Price: $9.59 --0%

Rating Summary:
    6 Buy, 22 Hold, 2 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
UBS maintains a 'Sell' on athenahealth (NASDAQ: ATHN) price target raised from $31 to $34.

UBS analyst says, "ATHN's 4Q11 revenue of $92.5 mil grew 33% y-o-y and was slightly ahead of the Street ($92.3 mil) but below UBSe ($93.1 mil). GM of 62.4% was 180 bps better than forecasted while SG&A (lower) and R&D (higher) essentially offset each other in our model. Given all the talk around investments pressuring margins, we believe the company has been very conservative with its forecasts as 4Q EBITDA margins were essentially in line with the 2 prior quarters. While 2012 guidance was unchanged, we have raised our 2012e EPS to $1.00 (from $0.96) due to this conservatism."

For an analyst ratings summary and ratings history on athenahealth click here. For more ratings news on athenahealth click here.

Shares of athenahealth closed at $64.01 yesterday.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Analyst Comments, Analyst EPS Change, Analyst EPS View, Analyst PT Change

Related Entities

UBS